Family Office Real Estate Daily · Family Office Real Estate Research Desk · Preview
Research Desk
A curated index of 20,204 CRE market research reports from the major institutional publishers — filterable by asset class, market and publisher. Editorial Family-Office interpretation layer is rolling out report-by-report.
Showing Family Office Briefings with a LP angle — each card surfaces how a family office could deploy capital in that market.
24 reports
Page 1 / 1- CBREMay 13, 2026
New York City Life Sciences Figures Q1 2026
LP:Investing as a passive LP in a life sciences fund could offer exposure to the sector with less operational involvement.
- SavillsApr 15, 2026
New York Q1 2026 Life Sciences Market Report
LP:As a passive LP, family offices can gain exposure to life sciences investments through established funds, though this approach offers less control.
- CBREFeb 11, 2026
New York City Life Sciences Figures Q4 2025
LP:As a passive LP, family offices can gain exposure to the life sciences sector through established funds, though this approach offers less control.
- SavillsJan 14, 2026
New York Q4 2025 Life Sciences Market Report
LP:As a passive LP, family offices might explore established funds focused on life sciences to gain exposure without direct management responsibilities.
- CBREOct 22, 2025
New York City Life Sciences Figures Q3 2025
LP:As a passive LP, family offices can gain exposure to the life sciences sector through established funds, though this approach offers less control.
- SavillsOct 10, 2025
New York Q3 2025 Life Sciences Market Report
LP:As a passive LP, family offices may find opportunities in established funds focused on life sciences, though this is the least emphasized strategy.
- CBREJul 25, 2025
New York City Life Sciences Figures Q2 2025
LP:As a passive LP, family offices can gain exposure to the life sciences sector by committing capital to established funds focused on this market.
- SavillsJul 12, 2025
New York Q2 2025 Life Sciences Market Overview
LP:Investing as a passive LP in a life sciences fund could offer exposure to the sector with less operational involvement.
- CBREMay 9, 2025
New York City Life Sciences Figures Q1 2025
LP:As a passive LP, family offices can gain exposure to the life sciences sector through established funds, though this approach offers less control.
- SavillsApr 11, 2025
New York Q1 2025 Life Sciences Market Overview
LP:As a passive LP, family offices might explore commitments to established life sciences funds to gain exposure without direct management responsibilities.
- CBREMar 7, 2025
New York City Life Sciences Figures YE 2024
LP:As a passive LP, family offices can gain exposure to the life sciences market through established funds focused on this sector.
- SavillsFeb 7, 2025
New York Q4 2024 Life Sciences Market Overview
LP:As a passive LP, family offices might explore commitments to established life sciences funds to gain exposure without direct management responsibilities.
- SavillsNov 6, 2024
New York Q3 2024 Life Sciences Market Report
LP:As a passive LP, family offices can gain exposure to the life sciences sector through established funds.
- CBREOct 23, 2024
New York City Life Sciences Figures Q3 2024
LP:As a passive LP, family offices can gain exposure to the life sciences sector through established funds focused on this market.
- CBREAug 9, 2024
New York City Life Sciences Figures Q2 2024
LP:Investing as a passive LP in a life sciences fund could provide exposure to the sector with less operational involvement.
- SavillsAug 7, 2024
New York Q2 2024 Life Sciences Market Report
LP:As a passive LP, family offices might explore established funds focused on life sciences to gain exposure without direct management responsibilities.
- SavillsMay 10, 2024
New York Q1 2024 Life Sciences Market Report
LP:As a passive LP, family offices can gain exposure to diversified life sciences funds that are actively investing in the New York market.
- CBREApr 19, 2024
New York City Life Sciences Figures Q1 2024
LP:As a passive LP, family offices can gain exposure to life sciences through established funds, though this approach may limit direct influence over asset management.
- CBREFeb 28, 2024
New York City Life Sciences 2023 Year End Report
LP:The passive LP angle may involve committing to a fund focused on life sciences, though this is less emphasized in the current market context.
- SavillsJan 31, 2024
New York Q4 2023 Life Sciences Market Report
LP:The passive LP angle may involve committing to a fund focused on life sciences, though this is less emphasized in the current market context.
- SavillsNov 3, 2023
New York 2023 Q3 Life Sciences Market Report
LP:As a passive LP, family offices might explore commitments to funds focused on life sciences to gain exposure to this dynamic sector.
- CBREOct 27, 2023
New York City Life Sciences Figures Q3 2023
LP:The passive LP angle could involve committing to a fund focused on life sciences, although this is less emphasized compared to direct or co-GP investments.
- CBREJul 12, 2023
New York City Life Sciences Figures Q2 2023
LP:The passive LP angle may involve committing to a life sciences fund managed by a reputable sponsor.
- CBREApr 25, 2023
New York City Life Sciences Figures Q1 2023
LP:As a passive LP, family offices can gain exposure to the life sciences market through established funds focused on this sector.
Research Hubs
Dedicated pages for every major publisher and market — each with aggregated KPI medians, asset-class breakdowns and the latest reports, read through a family-office lens.